Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) Operating Expenses (2023 - 2025)

Compass Therapeutics (CMPX) has disclosed Operating Expenses for 3 consecutive years, with $18.0 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 8.54% to $18.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $72.8 million through Dec 2025, up 26.73% year-over-year, with the annual reading at $72.8 million for FY2025, 26.73% up from the prior year.
  • Operating Expenses hit $18.0 million in Q4 2025 for Compass Therapeutics, up from $15.8 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $21.1 million in Q2 2025 to a low of $9.7 million in Q1 2023.
  • Historically, Operating Expenses has averaged $15.1 million across 3 years, with a median of $15.6 million in 2023.
  • Biggest five-year swings in Operating Expenses: increased 2.62% in 2024 and later surged 40.69% in 2025.
  • Year by year, Operating Expenses stood at $15.4 million in 2023, then rose by 7.67% to $16.6 million in 2024, then grew by 8.54% to $18.0 million in 2025.
  • Business Quant data shows Operating Expenses for CMPX at $18.0 million in Q4 2025, $15.8 million in Q3 2025, and $21.1 million in Q2 2025.